Galectin Therapeutics (NASDAQ:GALT) the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631 titled “Method and Treatment of Pulmonary Fibrosis.” The patent’s principal claims cover method of use of GR-MD-02 as a means to treat pulmonary fibrosis. … Continued